Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have been assigned an average rating of “Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $98.67.

A number of equities analysts have recently weighed in on BPMC shares. ValuEngine cut Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 24th. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Sunday, October 7th. Guggenheim started coverage on Blueprint Medicines in a report on Tuesday, September 18th. They issued a “buy” rating and a $102.00 price target for the company. BidaskClub raised Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Finally, Wedbush reissued an “outperform” rating and issued a $101.00 price target on shares of Blueprint Medicines in a report on Monday, October 22nd.

BPMC stock traded down $0.82 during midday trading on Monday, hitting $57.47. 314,842 shares of the stock were exchanged, compared to its average volume of 391,514. The stock has a market cap of $2.56 billion, a PE ratio of -14.66 and a beta of 1.42. Blueprint Medicines has a fifty-two week low of $50.51 and a fifty-two week high of $109.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.05 and a current ratio of 10.05.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.09). The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The business’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.96) earnings per share. As a group, equities research analysts predict that Blueprint Medicines will post -5.25 earnings per share for the current year.

In other news, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the completion of the transaction, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at $1,269,800. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Marion Dorsch sold 2,300 shares of the business’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $70.47, for a total value of $162,081.00. Following the completion of the transaction, the insider now directly owns 2,300 shares of the company’s stock, valued at $162,081. The disclosure for this sale can be found here. Insiders own 3.15% of the company’s stock.

Several large investors have recently made changes to their positions in BPMC. BlueMountain Capital Management LLC purchased a new stake in shares of Blueprint Medicines in the third quarter valued at $140,000. Bank of Montreal Can purchased a new stake in shares of Blueprint Medicines in the second quarter valued at $154,000. grace capital purchased a new stake in shares of Blueprint Medicines in the second quarter valued at $171,000. Jane Street Group LLC purchased a new stake in shares of Blueprint Medicines in the second quarter valued at $206,000. Finally, Fernwood Investment Management LLC purchased a new stake in shares of Blueprint Medicines in the third quarter valued at $210,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Article: Balanced Fund

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.